[
  {
    "ts": null,
    "headline": "Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win",
    "summary": "Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win",
    "url": "https://finnhub.io/api/news?id=d0a21e13b24efe600252e27b67244fd93ba80686025ab93d14aa9680fef45cee",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756224561,
      "headline": "Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win",
      "id": 136543756,
      "image": "",
      "related": "GILD",
      "source": "DowJones",
      "summary": "Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win",
      "url": "https://finnhub.io/api/news?id=d0a21e13b24efe600252e27b67244fd93ba80686025ab93d14aa9680fef45cee"
    }
  },
  {
    "ts": null,
    "headline": "GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU",
    "summary": "Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.",
    "url": "https://finnhub.io/api/news?id=75d9b24c0cd17c7275aa5e8b9b7aa3be07b187254ade510a67a413895da9bcca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756215600,
      "headline": "GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU",
      "id": 136526772,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.",
      "url": "https://finnhub.io/api/news?id=75d9b24c0cd17c7275aa5e8b9b7aa3be07b187254ade510a67a413895da9bcca"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s Yeytuo approved in EU, boosting its blockbuster potential",
    "summary": "Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.",
    "url": "https://finnhub.io/api/news?id=153fee7f95f02094b321efcf7e433cb7b8e6675acb1e4e6fb354098c1a7ba28e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756208613,
      "headline": "Gilead’s Yeytuo approved in EU, boosting its blockbuster potential",
      "id": 136525797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.",
      "url": "https://finnhub.io/api/news?id=153fee7f95f02094b321efcf7e433cb7b8e6675acb1e4e6fb354098c1a7ba28e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead wins European approval for HIV prevention injection",
    "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its twice-yearly injection to prevent HIV, a key regulatory milestone following its U.S. clearance earlier this year.",
    "url": "https://finnhub.io/api/news?id=7990e784668c48e45eba8901cbb7bda74bc4febf1896faa9c5672ea0c62346bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756198671,
      "headline": "Gilead wins European approval for HIV prevention injection",
      "id": 136524008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its twice-yearly injection to prevent HIV, a key regulatory milestone following its U.S. clearance earlier this year.",
      "url": "https://finnhub.io/api/news?id=7990e784668c48e45eba8901cbb7bda74bc4febf1896faa9c5672ea0c62346bb"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention",
    "summary": "FOSTER CITY, Calif., August 26, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for u",
    "url": "https://finnhub.io/api/news?id=e3a0e9b13b1244707b2cf0a5e082f7cbfac44658cb2405b1a0a2b1c5c49bfb2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756191600,
      "headline": "European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention",
      "id": 136524010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., August 26, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for u",
      "url": "https://finnhub.io/api/news?id=e3a0e9b13b1244707b2cf0a5e082f7cbfac44658cb2405b1a0a2b1c5c49bfb2d"
    }
  }
]